Tutorials
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

$ 288.03 +13.18 (+4.8%) 10:08 PM EST
On watch
P/E:
30.32
P/B:
6.75
Market Cap:
$ 73.67B
Enterprise V:
$ 64.94B
Volume:
2.40M
Avg Vol (2M):
1.63M
Also Trade In:
Volume:
2.40M
Market Cap $:
73.67B
PE Ratio:
30.32
Avg Vol (2-Month):
1.63M
Enterprise Value $:
64.94B
PB Ratio:
6.75
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Vertex Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
50 Northern Avenue, Boston, MA, USA, 02210
Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Financials (Next Earnings Date:2022-11-02 Est.)

VRTX's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:VRTX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 7,947.595
EPS (TTM) ($) 9.5
Beta 0.26
Volatility % 26.85
14-Day RSI 56.76
14-Day ATR ($) 8.012446
20-Day SMA ($) 284.104
12-1 Month Momentum % 42.36
52-Week Range ($) 176.36 - 296.8409
Shares Outstanding (Mil) 255.76

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Vertex Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More